Skip to main content

Advertisement

Table 1 Clinicopathologic and demographic characteristics of recipients, donors and transplant compared between T1DM und T2DM

From: Short and long-term metabolic outcomes in patients with type 1 and type 2 diabetes receiving a simultaneous pancreas kidney allograft

VariablesT1DM SPK (n = 89)T2 DM SPK (n = 12)T2DM KTA (n = 26)p-value
Age at onset of diabetes mellitus, years15.9 +/−  9.128.6 +/−  10.941.2 +/−  12.4< 0.01
Recipient age, years42.3+/−  8.448.7+/−  10.661.5+/− 8.6< 0.01
Recipient gender   0.04
 Male49 (55.1%)8 (66.7%)21 (80.8%) 
 Female40 (44.9%)4 (33.3%)5 (19.2%) 
Recipient BMI (kg/m2)24.8 +/− 4.126.4 +/− 4.928.6 +/− 3.1< 0.01
Duration of Diabetes mellitus, years27.6 +/− 7.918.7 +/− 9.818.9 +/− 8.9< 0.01
Insulin amount, IU/d47.9 +/− 22.337.1 +/− 18.142.1 +/− 19.3n.s.
Donor age, years23.9 +/−  11.717.3 +/−  12.159.7 +/−  17.4< 0.01
Donor BMI (kg/m2)22.5 +/− 3.522.1 +/− 2.625.4 +/−  3.5< 0.01
Donor, gender   n.s.
Male56 (62.9%)4 (33.3%)12 (46.2%) 
Female33 (37.1%)8 (66.7%)14 (53.8%) 
Donor- Cause of Death, CVA %26 (29.2%)5 (41.7%)15 (57.7%)0.03
CIT Pancreas, hours10.7 +/− 2.610.9 +/− 2.4N.A.n.s.
CIT kidney, hours11.2 +/− 3.211.7 +/− 2.811.3 +/− 4.9n.s.
Waiting time, months7.8 +/− 10.415.1 +/− 16.422.3 +/−  28.40.01
Petransplant dialysis duration, months31.54 +/−35.1940.58 +/−  23.388.28 +/−  49.1< 0.01
Pre-emptive transplant22 (24.7%)0 (0%)2 (7.7%)0.03
Systolic blood pressure, mmHG134 +/− 17138 +/− 21141 +/−  180.04
Diastolic blood pressure, mmHG76 +/− 879 +/− 1182 +/− 110.03
HbA1c pretransplantation,%7.9 +/− 1.76.6 +/− 1.46.7 +/− 0.90.01
C-Peptid, ng/ml0.15 +/− 0.43.2 +/− 1.1< 0.01
Total cholesterol,5.2 +/− 1.45.6 +/−  0.84.9 +/−  1.6n.s.
Triglyceride,1.9 +/− 1.12.5 +/− 1.72.6 /−  1.20.04
LDL- cholesterol,2.8 +/− 0.92.9 +/− 1.12.8 +/− 1.4n.s.
HDL- cholesterol,1.5 +/− 0.41.2 +/− 0.31.2 +/−  0.40.02
Arterial obstructive disease   0.04
 Yes15 (16.9%)2 (16.7%)10 (40%) 
 No74 (83.1%)10 (83.3%)15 (60%) 
Coronary heart disease   < 0.01
 Yes23 (25.8%)6 (50%)19 (73.1%) 
 No66 (74.2%)6 (50%)7 (26.9%) 
CABG/stent   < 0.01
 Yes15 (83.1%)4 (33.3%)16 (64%) 
 No74 (16.9%)8 (66.7%)9 (36%) 
Retinopathy   < 0.01
 Yes78 (87.6%)8 (66.7%)10 (38.5%) 
 No11 (12.4%)4 (33.3%)16 (61.5%) 
Neuropathy   n.s.
 Yes55 (73.3%)9 (75%)12 (46.2%) 
 No34 (38.9%)3 (25%)14 (53.8%) 
Nephropathy   N.A.
 Yes89 (100%)12 (100%)26 (100%) 
 No0 (0%)0 (0%)0 (0%) 
Number of antihypertensive drugs   n.s.
 014 (15.7%)3 (25%)9 (34.6%) 
 16 (6.7%)1 (8.3%)2 (7.7%) 
 214 (15.7%)2 (16.7%)6 (23.1%) 
 324 (27%)2 (16.7%)5 (19.2%) 
 418 (20.2%)1 (8.3%)2 (7.7%) 
  > 413 (14.6%)3 (25%)2 (7.7%) 
Panel reactive antibodies (PRA), %75 (85.2%)12 (100%)19 (73.1%)n.s.
010 (11.4%05 (19.2%) 
1–20 > 203 (3.4%)02 (7.7%) 
HLA-DR mismatch; n1.3 +/− 0.51.1 +/− 0.42.3 +/− 1.4< 0.01
CNI   n.s.
 Tacrolimus85 (95.5%)12 (100%)25 (96.2%) 
 Cyclosporin4 (4.5%)0 (0%)1 (4.5%) 
Induction Therapy   < 0.01
 ALG/ATG63 (70.8%)11 (91.7%)4 (15.4%) 
 IL2-RA19 (21.3%)0 (0%)12 (46.2%) 
 None7 (7.9%)1 (8.3%)10 (38.5%) 
AP drug   0.01
 MMF72 (80.9%)11 (91.7%)22 (84.6%) 
 SRL13 (14.6%)1 (8.3%)0 
 Multiple3 (3.4%)00 
 NONE1 (0.8%)04 (15.4%)